PubRank

Giovanna Damia

Author PubWeight™ 23.76‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Epithelial-mesenchymal transition and breast cancer: role, molecular mechanisms and clinical impact. Cancer Treat Rev 2011 1.63
2 Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo. Cell Cycle 2012 1.44
3 Unleashing Chk1 in cancer therapy. Cell Cycle 2011 1.44
4 E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res 2011 1.28
5 Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents: differential activity in cells expressing or not p53. Cell Cycle 2004 1.22
6 A work in progress: the clinical development of histone deacetylase inhibitors. Epigenetics 2008 1.14
7 Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis. Dig Liver Dis 2010 1.09
8 Characterization of the 5'flanking region of the human Chk1 gene: identification of E2F1 functional sites. Cell Cycle 2003 1.03
9 Checkpoint kinase 1 down-regulation by an inducible small interfering RNA expression system sensitized in vivo tumors to treatment with 5-fluorouracil. Clin Cancer Res 2008 1.02
10 International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). J Natl Cancer Inst Monogr 2011 1.00
11 Unique features of the mode of action of ET-743. Oncologist 2002 0.97
12 Ovarian carcinoma tumor-initiating cells have a mesenchymal phenotype. Cell Cycle 2012 0.94
13 The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts. Mol Cancer Ther 2012 0.92
14 U2OS cells lacking Chk1 undergo aberrant mitosis and fail to activate the spindle checkpoint. J Cell Mol Med 2009 0.91
15 Revisiting ovarian cancer preclinical models: implications for a better management of the disease. Cancer Treat Rev 2013 0.84
16 ALDH enzymatic activity and CD133 positivity and response to chemotherapy in ovarian cancer patients. Am J Cancer Res 2013 0.83
17 Chk1-Mad2 interaction: a crosslink between the DNA damage checkpoint and the mitotic spindle checkpoint. Cell Cycle 2013 0.83
18 Variolin B and its derivate deoxy-variolin B: new marine natural compounds with cyclin-dependent kinase inhibitor activity. Eur J Cancer 2005 0.82
19 HPLC-MS/MS method for quantitative determination of the novel dual inhibitor of FGF and VEGF receptors E-3810 in tumor tissues from xenograft mice and human biopsies. J Mass Spectrom 2014 0.80
20 Benzylidenetetralones, cyclic chalcone analogues, induce cell cycle arrest and apoptosis in HCT116 colorectal cancer cells. Tumour Biol 2014 0.79
21 Triple negative breast cancers have a reduced expression of DNA repair genes. PLoS One 2013 0.79
22 Role of Chk1 in the differentiation program of hematopoietic stem cells. Cell Mol Life Sci 2010 0.77
23 Is PDGFR an important target for E-3810? J Cell Mol Med 2012 0.75
24 Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancer. Cancer Manag Res 2013 0.75
25 Correction: Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle. Oncotarget 2016 0.75
26 Tumor shrinkage and improved quality of life in a heavily pretreated metastatic breast cancer patient treated with eribulin. Future Oncol 2013 0.75